{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:00:40Z","timestamp":1787029240842,"version":"build-2736575974"},"reference-count":51,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2018R1A5A2023127"],"award-info":[{"award-number":["NRF-2018R1A5A2023127"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>EphB3 is a major key player in a variety of cellular activities, including cell migration, proliferation, and apoptosis. However, the exact role of EphB3 in cancer remains ambiguous. Accordingly, new EphB3 inhibitors can increase the understanding of the exact roles of the receptor and may act as promising therapeutic candidates. Herein, a hybrid approach of structure-based design and virtual combinatorial library generated 34 quinazoline sulfonamides as potential selective EphB3 inhibitors. A molecular docking study over EphB3 predicted the binding affinities of the generated library, and the top seven hit compounds (3a and 4a\u2013f), with GlideScore \u2265 \u22126.20 Kcal\/mol, were chosen for further MM-GBSA calculations. Out of the seven top hits, compound 4c showed the highest MM-GBSA binding free energy (\u221274.13 Kcal\/mol). To validate these predicted results, compounds 3a and 4a\u2013f were synthesized and characterized using NMR, HRMS, and HPLC. The biological evaluation revealed compound 4c as a potent EphB3 inhibitory lead (IC50 = 1.04 \u00b5M). The screening of 4c over a mini-panel of kinases consisting of EGFR, Aurora A, Aurora B, CDK2\/cyclin A, EphB1, EphB2, EphB4, ERBB2\/HER2, and KDR\/VEGFR2, showed a promising selective profile against EphB3 isoform. A dose-dependent assay of compound 4c and a molecular docking study over the different forms of EphB provided insights into the elicited biological activities and highlighted reasonable explanations of the selectivity.<\/jats:p>","DOI":"10.3390\/ph14121247","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T23:22:56Z","timestamp":1638314576000},"page":"1247","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Hit Identification of a Novel Quinazoline Sulfonamide as a Promising EphB3 Inhibitor: Design, Virtual Combinatorial Library, Synthesis, Biological Evaluation, and Docking Simulation Studies"],"prefix":"10.3390","volume":"14","author":[{"given":"Kyeong","family":"Lee","sequence":"first","affiliation":[{"name":"BK21 FOUR Team and Integrated Research Institute for Drug Development, College of Pharmacy, Dongguk University-Seoul, Goyang 10326, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4882-5621","authenticated-orcid":false,"given":"Hossam","family":"Nada","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Dongguk University-Seoul, Goyang 10326, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Jung","family":"Byun","sequence":"additional","affiliation":[{"name":"BK21 FOUR Team and Integrated Research Institute for Drug Development, College of Pharmacy, Dongguk University-Seoul, Goyang 10326, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2210-0793","authenticated-orcid":false,"given":"Chang Hoon","family":"Lee","sequence":"additional","affiliation":[{"name":"BK21 FOUR Team and Integrated Research Institute for Drug Development, College of Pharmacy, Dongguk University-Seoul, Goyang 10326, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7398-6155","authenticated-orcid":false,"given":"Ahmed","family":"Elkamhawy","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Dongguk University-Seoul, Goyang 10326, Korea"},{"name":"Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrc2806","article-title":"Eph receptors and ephrins in cancer: Bidirectional signalling and beyond","volume":"10","author":"Pasquale","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/bcr2207","article-title":"Eph receptors in breast cancer: Roles in tumor promotion and tumor suppression","volume":"10","author":"Vaught","year":"2008","journal-title":"Breast Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10735-006-9067-0","article-title":"EphB3 receptor and ligand expression in the adult rat brain","volume":"37","author":"Willson","year":"2006","journal-title":"J. Mol. Histol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.3389\/fimmu.2019.01473","article-title":"Emerging Roles for Eph Receptors and Ephrin Ligands in Immunity","volume":"10","author":"Darling","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/0008-5472.CAN-10-0717","article-title":"EphB3 is overexpressed in non-small-cell lung cancer and promotes tumor metastasis by enhancing cell survival and migration","volume":"71","author":"Ji","year":"2011","journal-title":"Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.biocel.2018.07.008","article-title":"Upregulation of EphB3 in gastric cancer with acquired resistance to a FGFR inhibitor","volume":"102","author":"Lee","year":"2018","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Jang, B.G., Kim, H.S., Bae, J.M., Kim, W.H., Hyun, C.L., and Kang, G.H. (2020). Expression Profile and Prognostic Significance of EPHB3 in Colorectal Cancer. Biomolecules, 10.","DOI":"10.3390\/biom10040602"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1158\/1535-7163.MCT-17-1163","article-title":"Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor","volume":"17","author":"Bhatia","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.gene.2018.11.015","article-title":"EZH2-mediated epigenetic suppression of EphB3 inhibits gastric cancer proliferation and metastasis by affecting E-cadherin and vimentin expression","volume":"686","author":"Zhao","year":"2019","journal-title":"Gene"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1074\/jbc.M116.750349","article-title":"EphB3 Stimulates Cell Migration and Metastasis in a Kinase-dependent Manner through Vav2-Rho GTPase Axis in Papillary Thyroid Cancer","volume":"292","author":"Li","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cas.13161","article-title":"EphB3-targeted regulation of miR-149 in the migration and invasion of human colonic carcinoma HCT116 and SW620 cells","volume":"108","author":"Zhang","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/ijc.25147","article-title":"The role of Eph receptors and ephrin ligands in colorectal cancer","volume":"126","author":"Herath","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/carcin\/bgp133","article-title":"Over-expression of EphB3 enhances cell\u2013cell contacts and suppresses tumor growth in HT-29 human colon cancer cells","volume":"30","author":"Chiu","year":"2009","journal-title":"Carcinogenesis"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/ncomms1675","article-title":"EphB3 suppresses non-small-cell lung cancer metastasis via a PP2A\/RACK1\/Akt signalling complex","volume":"3","author":"Li","year":"2012","journal-title":"Nat. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"10554","DOI":"10.1021\/jacs.6b05483","article-title":"Development of Specific, Irreversible Inhibitors for a Receptor Tyrosine Kinase EphB3","volume":"138","author":"Kung","year":"2016","journal-title":"J. Am. Chem. Soc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1080\/15476278.2017.1389368","article-title":"EphB receptors, mainly EphB3, contribute to the proper development of cortical thymic epithelial cells","volume":"13","author":"Zapata","year":"2017","journal-title":"Organogenesis"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2147\/CMAR.S232278","article-title":"Prognostic and Clinicopathological Significance of EphB3 and Dysadherin Expression in Extrahepatic Cholangiocarcinoma","volume":"12","author":"Wu","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10456-010-9183-z","article-title":"The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis","volume":"13","author":"Holzer","year":"2010","journal-title":"Angiogenesis"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"104745","DOI":"10.18632\/oncotarget.20065","article-title":"Discovery and evaluation of triple inhibitors of VEGFR-2, TIE-2 and EphB4 as anti-angiogenic and anti-cancer agents","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s10637-015-0288-5","article-title":"A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-\u03b2, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort","volume":"33","author":"Werner","year":"2015","journal-title":"Investig. New Drugs"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/JTO.0b013e31822eebf9","article-title":"XL647\u2014A multitargeted tyrosine kinase inhibitor: Results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib","volume":"7","author":"Pietanza","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1007\/s11033-020-05470-y","article-title":"The critical role of the interplays of EphrinB2\/EphB4 and VEGF in the induction of angiogenesis","volume":"47","author":"Du","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1007\/s10637-011-9640-6","article-title":"Discovery of LY2457546: A multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model","volume":"30","author":"Burkholder","year":"2012","journal-title":"Investig. New Drugs"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.chembiol.2006.05.008","article-title":"MASPIT: Three-hybrid trap for quantitative proteome fingerprinting of small molecule-protein interactions in mammalian cells","volume":"13","author":"Caligiuri","year":"2006","journal-title":"Chem. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1016\/j.bmcl.2009.05.029","article-title":"Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors","volume":"19","author":"Choi","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.semcdb.2011.10.023","article-title":"Targeting Eph receptors with peptides and small molecules: Progress and challenges","volume":"23","author":"Noberini","year":"2012","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nrd4175","article-title":"Therapeutic targeting of EPH receptors and their ligands","volume":"13","author":"Boyd","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1016\/j.bmcl.2009.09.010","article-title":"Structure\u2013activity relationship study of EphB3 receptor tyrosine kinase inhibitors","volume":"19","author":"Qiao","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.bmcl.2006.09.050","article-title":"Design and effective synthesis of novel templates, 3,7-diphenyl-4-amino-thieno and furo-[3,2-c]pyridines as protein kinase inhibitors and in vitro evaluation targeting angiogenetic kinases","volume":"17","author":"Miyazaki","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/BF00228148","article-title":"AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR","volume":"8","author":"Laskowski","year":"1996","journal-title":"J. Biomol. NMR"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"107105","DOI":"10.1016\/j.compbiolchem.2019.107105","article-title":"An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction","volume":"83","author":"Sirous","year":"2019","journal-title":"Comput. Biol. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1517\/13543776.2015.1039512","article-title":"Quinazoline derivatives as anticancer drugs: A patent review (2011\u2013present)","volume":"25","author":"Ravez","year":"2015","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.bmc.2011.10.085","article-title":"Design and synthesis of 4,6-substituted-(diaphenylamino)quinazolines as potent EGFR inhibitors with antitumor activity","volume":"20","author":"Li","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2174\/092986711794940824","article-title":"Novel Substituted Quinazolines for Potent EGFR Tyrosine Kinase Inhibitors","volume":"18","author":"Nunez","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.bioorg.2019.01.017","article-title":"EGFR inhibitors from cancer to inflammation: Discovery of 4-fluoro-N-(4-(3-(trifluoromethyl)phenoxy)pyrimidin-5-yl)benzamide as a novel anti-inflammatory EGFR inhibitor","volume":"86","author":"Elkamhawy","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1021\/acs.jcim.8b00222","article-title":"Determination of a Focused Mini Kinase Panel for Early Identification of Selective Kinase Inhibitors","volume":"58","author":"Bembenek","year":"2018","journal-title":"J. Chem. Inf. Model."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/j.bmcl.2019.05.025","article-title":"Utilizing comprehensive and mini-kinome panels to optimize the selectivity of quinoline inhibitors for cyclin G associated kinase (GAK)","volume":"29","author":"Asquith","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5861","DOI":"10.1016\/j.bmcl.2009.08.083","article-title":"Small kinase assay panels can provide a measure of selectivity","volume":"19","author":"Brandt","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","article-title":"A small molecule\u2013kinase interaction map for clinical kinase inhibitors","volume":"23","author":"Fabian","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e2016265118","DOI":"10.1073\/pnas.2016265118","article-title":"Identification of tetracycline combinations as EphB1 tyrosine kinase inhibitors for treatment of neuropathic pain","volume":"118","author":"Ahmed","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1038\/sj.emboj.7601315","article-title":"A change in conformational dynamics underlies the activation of Eph receptor tyrosine kinases","volume":"25","author":"Wiesner","year":"2006","journal-title":"EMBO J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/pro.2445","article-title":"Completing the structural family portrait of the human EphB tyrosine kinase domains","volume":"23","author":"Overman","year":"2014","journal-title":"Protein Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"7260","DOI":"10.1016\/j.bmc.2010.08.017","article-title":"Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5H-pyrrolo [3,2-d]pyrimidine derivatives: Novel VEGFR2 kinase inhibitors binding to inactive kinase conformation","volume":"18","author":"Oguro","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1021\/jm100262j","article-title":"Imidazo[4,5-b]pyridine Derivatives As Inhibitors of Aurora Kinases: Lead Optimization Studies toward the Identification of an Orally Bioavailable Preclinical Development Candidate","volume":"53","author":"Bavetsias","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1042\/BJ20102097","article-title":"Structures of the substrate-binding protein provide insights into the multiple compatible solute binding specificities of the Bacillus subtilis ABC transporter OpuC","volume":"436","author":"Du","year":"2011","journal-title":"Biochem. J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1432-1033.1997.0518a.x","article-title":"Inhibition of Cyclin-Dependent Kinases by Purine Analogues","volume":"243","author":"Leclerc","year":"1997","journal-title":"Eur. J. Biochem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1021\/ci300425v","article-title":"MM\/GBSA Binding Energy Prediction on the PDBbind Data Set: Successes, Failures, and Directions for Further Improvement","volume":"53","author":"Greenidge","year":"2013","journal-title":"J. Chem. Inf. Model."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ejmech.2018.08.020","article-title":"Design, synthesis and biological evaluation of novel thiazolidinedione derivatives as irreversible allosteric IKK-\u03b2 modulators","volume":"157","author":"Elkamhawy","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1016\/j.bmcl.2015.10.003","article-title":"Targeting EGFR\/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking","volume":"25","author":"Elkamhawy","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1246\/cl.160349","article-title":"Synthesis of Diverse Benzotriazoles from Aryne Precursors Bearing an Azido Group via Inter- and Intramolecular Cycloadditions","volume":"45","author":"Yoshida","year":"2016","journal-title":"Chem. Lett."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/12\/1247\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:38:00Z","timestamp":1760168280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/12\/1247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,30]]},"references-count":51,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["ph14121247"],"URL":"https:\/\/doi.org\/10.3390\/ph14121247","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,30]]}}}